Inicio・Lista de Acciones・Glaukos Corp

Glaukos Corp

Cerrado

SectorSanidad

179.18 4.99

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

170.88

Máximo

180.24

Métricas clave
By Trading Economics
Ingresos	1.4M -18M
Ventas	35M 186M
BPA	-0.14
Margen de beneficios	-9.901
Empleados	1,094
EBITDA	-11M -16M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+3.83% upside

Dividendos
By Acuity
Próximas Ganancias	28 oct 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.2B 10B
Apertura anterior	174.19
Cierre anterior	179.18

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

124 / 340 Clasificación en Healthcare

Glaukos Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2026, 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4 ago 2026, 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3 ago 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 jul 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 jul 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 jul 2026, 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 jul 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 jul 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 jul 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 jul 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Comparación entre iguales

Cambio de precio

Glaukos Corp previsión

Precio Objetivo

By TipRanks

3.83% repunte

Estimación a 12 Meses

Media 186.92 USD 3.83%

Máximo 215 USD

Mínimo 153 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Glaukos Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Glaukos Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

124 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.